Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-04-26
1997-05-20
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514258, A61K 3152, A61K 31505
Patent
active
056312580
ABSTRACT:
This invention relates to methods of effecting immunosuppression and inhibiting tumor necrosis factor .alpha. in a patient in need thereof comprising administering to said patient an effective immunosuppressive amount of a compound of the formula ##STR1## wherein the hydroxy substituent on the cyclopentanyl ring is in the CIS configuration relative to the bicyclic substituent,
REFERENCES:
patent: 3917837 (1975-11-01), Lin et al.
patent: 4076711 (1978-02-01), Ganguly et al.
patent: 4386093 (1983-05-01), Chiang et al.
patent: 4387228 (1983-06-01), Montgomery et al.
patent: 4742064 (1988-05-01), Vince et al.
patent: 4845215 (1989-07-01), Shimada et al.
patent: 4859677 (1989-08-01), Borchardt et al.
patent: 4916224 (1990-04-01), Vince et al.
patent: 4954504 (1990-09-01), Chen et al.
patent: 4968674 (1990-11-01), Taniyama et al.
patent: 4997924 (1991-03-01), Jarvi et al.
patent: 5039689 (1991-08-01), Daluge
patent: 5126452 (1992-06-01), Vince et al.
Kelley, G.G., et al. The Effects of a Series of 9-Alkylpurines on the Growth of Sensitive and 6--MP-resistant H.Ep. #2 Cells. Cancer Research vol. 22, Apr. 1962, pp. 329-333 (1962).
Victor E. Marquez and Mu-III Lim. Medicinal Research Reviews, vol. 6, No. 1, 1-40 (1986). Carbocyclic Nucleosides, pp. 1-40.
European Patent Office, Decisions IIC vol. 17 No. May 1986, pp. 630-635, (1986).
Sircar et al., Drugs of The Future, 13(7):653-668 (1988), "Purine Nucleoside Phosphorylase (PNP) Inhibitors: Potentially Selective Immunosuppressive Agents".
Parks et al., Annals New York Academy of Sci., pp. 412-434 (1975), "Incorporation of Analog Purine Nucleosides Into The Formed Elements of Human Blood: Erythrocytes, Platelets, and Lymphocytes".
Polmar, et al., Dev. Pharmacol., 2:249-259 (1983), "Adenosine and Cyclic Nucleotides in Modulation of Immune Responses".
Trost, et al., J. Am. Chem. Soc. vol. 110, 621-622, (1988).
Hasobe, et al., FASEB Journal vol. 4, A1771 (Abstr. #455) (1990).
Ault-Riche, et al., FASEB Journal vol. 4, A2050 (Abstr. #2064) (1990).
Wolf, et al., 199th ACS National Meeting, Boston, Mass., Apr. 1990, Abstract #27.
Koga, et al., Tetrahedron Letters, vol. 31, No. 41, pp. 5861-5864, 1990.
A Dictionary of Immunology, Herbert et al., p. 112, 1971.
Dictionary of Immunology, Rosen et al., ed, 1989, pp. 9, 18, 69-70, 155, 188.
Recent Advantages in Immunology, Muftuoglu et al., ed., 1984, Plenum Press, pp. 191-209.
Introduction to Human Immunology, Huffer et al., 1986, pp. 148-161, 169-176.
Derwent Abstract 70718Y/40, Mar. 1977, 1977.
Derwent Abstract 70719Y/40, Apr. 1976, 1977.
Rousseau, R.J., and Robins, R.K., J. Hetero. Chem., 2, 196, (1965).
Borcherding David R.
Edwards III Carl K.
Esser Ronald E.
Cintins Marianne M.
Jarvis William R. A.
Merrell Pharmaceuticals Inc.
Payne T. Helen
LandOfFree
Method of effecting immunosuppression by administering carbocycl does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of effecting immunosuppression by administering carbocycl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of effecting immunosuppression by administering carbocycl will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1724077